Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTsp Advanced Technologies Plc Regulatory News (TSP.PL)

Share Price Information for Tsp Advanced Technologies Plc (TSP.PL)

Share Price is delayed by 15 minutes
Get Live Data
0.40    0.00 (0.00%)
Bid:
0.30
Ask:
0.50
Spread: 0.20 (66.667%)
Market Cap: £749.20k
TSP.PL Live PriceLast checked at - Aquis Stock Exchange

Intraday Tsp Advanced Technologies Plc Share Chart

Issue of Equity

25 Apr 2025 11:32

RNS Number : 2571G
TruSpine Technologies PLC
25 April 2025
 

25 April 2025

TruSpine Technologies plc

("TruSpine" or the "Company")

 

Issue of Equity

 

TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces that on 28 March 2025, the Company issued 7,103,623 new ordinary shares ("Creditor Shares") of 0.01 pence each at a price of 1.5 pence per Creditor Share to settle creditor liabilities of approximately £106,554. Due to an administrative oversight by the Company, no announcement or application was made for these shares to be admitted to trading on the AQSE Market.

 

Admission

 

Application has now been made for the Creditor Shares to be admitted to trading on the Aquis Stock Exchange AQSE Growth Market on or around 1 May 2025 ("Admission") and will rank pari passu with the ordinary shares of the Company in issue.

 

Total Voting Rights

 

Following Admission, the Company's issued share capital will comprise 160,131,523 ordinary shares of 0.01p each, with each share carrying the right to one vote, therefore the total number of voting rights in the Company will be 160,131,523. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in the Company, or a change to their interest in the Company, under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

-END-

TruSpine Investor Hub 

https://investorhub.truspinetech.com

TruSpine Technologies Plc

Tel: +44 (0)20 7118 0852

Geoff Miller, Non-executive Chairman

Cairn Financial Advisers LLP (AQSE Corporate Adviser)

Tel: +44 (0)20 7213 0880

Liam Murray / Ludovico Lazzaretti

Peterhouse Capital Limited (Broker & Financial Adviser)

 Tel: +44 (0)20 7469 0930

Lucy Williams / Duncan Vasey

 

Novus Communications (PR and IR)

Tel: +44 (0)1273 704 473

Alan Green / Jacqueline Briscoe

 J.Briscoe@novuscomms.com

 

 

 

Caution regarding forward looking statements

 

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXFLFFISAIEFIE
12
Date   Source Headline
21st Feb 20243:57 pmRNSNotice of Adjourned AGM
19th Feb 20247:00 amRNSFDA Update
14th Feb 20247:00 amRNSConvertible Loan, Loan Update, AGM Update and RPT
5th Jan 20247:00 amRNSLoan, Related Party Transaction and FDA Update
28th Dec 20237:00 amRNSHalf-year Report
27th Nov 20237:00 amRNSCompany Update
30th Oct 20237:00 amRNSFurther re: FDA Update
25th Oct 20238:37 amRNSIP Registration
12th Oct 20237:00 amRNSFurther re: FDA Update
3rd Oct 20237:00 amRNSFurther re: FDA Update
29th Sep 20237:00 amRNSFinal Results
18th Sep 20237:00 amRNSProposed Director Appointments & Update
17th Aug 20231:39 pmRNSResult of Aquis Disciplinary Investigation
15th Aug 20237:00 amRNSSubscription
25th Jul 20237:00 amRNSFurther re: FDA Update
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.